Effects of Pueraria Mirifica on cholesterol levels in postmenopausal women
Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women
This study is testing if taking Pueraria Mirifica capsules can help lower cholesterol and improve heart health in postmenopausal women.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Sex | Female |
| Sponsor | Dhurakij Pundit University Academic / other |
| Locations | 1 site (Laksi, Bangkok) |
| Trial ID | NCT06220266 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the impact of phytoestrogen derived from Pueraria Mirifica on serum lipid parameters in postmenopausal women. Participants will take capsules containing 50 mg of Pueraria Mirifica twice daily for two months, while also following a diet control and lifestyle modification program. The study aims to determine if this intervention can lower triglycerides, total cholesterol, and LDL levels, while increasing HDL levels. Additionally, it will assess the effects on menopausal symptoms, body mass index, waist circumference, blood pressure, and kidney and liver function.
Who should consider this trial
Good fit: Ideal candidates are postmenopausal women with abnormal lipid profiles who have not received lipid-lowering medications or hormone therapies recently.
Not a fit: Patients with a history of cancer, uncontrolled diabetes, or serious medical conditions requiring close monitoring may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a natural alternative for improving lipid profiles and overall health in postmenopausal women.
How similar studies have performed: Other studies have shown promising results with phytoestrogens in managing lipid levels, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Natural menopause, last menstrual period more than one year ago. 2. Abnormal lipid profile parameters The criteria set for this research are: * LDL\>130 mg/Dl or * TG\>150 mg/Dl or * Total cholesterol\>200 mg/Dl or * HDL-C less than 50 mg/Dl. (Latest blood results not more than 6 months) 3. Willing to participate in the project Exclusion Criteria: 1. Have ever received lipid-lowering medication or hormone replacement therapy or SERMs. During the past 6 weeks 2. have had surgery on the ovaries or uterus before 3. have a history of cancer within a 5-year period 4. have diabetes or uncontrolled high blood pressure, including HbA1c \>9, Systolic blood pressure \>180 or Diastolic blood pressure \>110 5. Endocrine system disease such as thyroid 6. Ever had an organ transplant 7. Regularly use drugs, marijuana, or drink alcohol. 8. has a psychiatric disorder 9. have other serious medical conditions that require close monitoring 10. Inconvenient to follow up until the end of the research.
Where this trial is running
Laksi, Bangkok
- Dhurakij Pundit University — Laksi, Bangkok, Thailand (Recruiting)
Study contacts
- Principal investigator: Prischa Saengow, MD. — Dhurakij Pundit University
- Study coordinator: Prischa Saengow, MD.
- Email: purnprattana@gmail.com
- Phone: +66-65-2162299
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.